Company / Debt per Share
Sarepta Therapeutics Debt per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Debt per Share
$1.45
FY2025
5-year range
$1.45 / $17.72
FY2021-FY2025
Trend
-88.0%
vs FY2024
Sector context
#51 of 82
Health Care
What the data says
At $1.45, Sarepta Therapeutics's debt per share ranks #32 of 82 in the Health Care sector. Debt per Share has declined for 3 consecutive years, from $17.72 in FY2022 to $1.45 in FY2025.
Based on SEC 10-K filings.
1.45 in FY2025 with a 3-year CAGR of -56.6%.
Improved from $14.08 to $1.45 over the past 2 years.
Health Care sector context is included.
Debt per Share over time
Growth rates
- 3-Year CAGR
- -56.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#32 of 82 in Health CareTop 38% of 82This company $1.45 Sector average $151.59
▼
-99.0% below sector average
Key checks
Key Insights
- Sarepta Therapeutics's debt per share has declined for 3 consecutive years.
- In FY2025, debt per share decreased 88.0% year-over-year.
- Ranks #51 out of 82 companies in the Health Care sector.
- Peak debt per share was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.45 | -88.0% |
| FY2024 | $12.13 | -13.8% |
| FY2023 | $14.08 | -20.6% |
| FY2022 | $17.72 | +149.6% |
| FY2021 | $7.10 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | $6.49 | -17.5% |
| FY2017 | $7.87 | +1933.0% |
| FY2016 | $0.39 | -39.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026